Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations

por Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, O G, Rieger, M A
Publicado 2017

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

por Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
Publicado 2016

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

por Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H, Ottmann, O G
Publicado 2017

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

por Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G
Publicado 2017